ESHAP

ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin disease. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.[1]

[R]-ESHAP consists of:

  1. (R)ituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes
  2. (E)toposide, an epipodofyllotoxin topoisomerase inhibitor
  3. (S)olu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes
  4. (H)igh-dose (A)ra-C - cytarabine
  5. (P)latinol - Cisplatin, an platinum-based antineoplastic agent with an alkylating mechanism;

Dosing regimen

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 0
(E)toposide 40 mg/m2 IV infusion over 1 hr Days 1-4
(S)olu-Medrol - Methylprednisolone 500 mg IV bolus over 15 min Days 1-5
(H)igh-dose (A)ra-C — cytarabine 2000 mg/m2 IV infusion over 2 hrs Day 5
Platinol (cisplatin) 25 mg/m2 IV continuous infusion over 24 hrs Days 1-4

References

  1. ↑ ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
This article is issued from Wikipedia - version of the 9/18/2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.